Soleno Therapeutics, Inc. (NASDAQ: SLNO) Overview and Financial Highlights

Core Insights - Soleno Therapeutics has been upgraded to "Overweight" by Wells Fargo, with a revised price target of $106 from $123, while the stock price is currently at $63.85 [1][6] - The company reported a net revenue of $66 million and a net income of $26 million in Q3 2025, primarily driven by VYKAT XR sales [3][6] - Soleno has engaged 494 unique prescribers and has 764 active patients on VYKAT XR since its approval in March 2025 [3][6] Financial Performance - In Q3 2025, Soleno achieved net revenue of $66 million from VYKAT XR sales, resulting in a positive net income of $26 million [3][6] - The stock price has decreased by 2.74% today, with a trading range between $63.81 and $67.43, and a market capitalization of approximately $3.39 billion [4] Strategic Developments - Soleno has appointed Mark W. Hahn to its Board of Directors and Audit Committee to enhance its strategic direction and governance [5] - The company has covered over 132 million lives under its initiatives, indicating an expansion in its reach within the biopharmaceutical industry [5]